Registrant : Organisation or self-employed individual
| Name/company name: |
Astellas Pharma Europe Ltd |
| Acronym: |
|
| Legal status: |
.
|
| Website address: |
|
Sections
| Section: |
II - In-house lobbyists and trade/professional associations |
| and more precisely: |
Companies & groups |
Person with legal responsibility
| Surname, Name: |
Mr
Jerry Temko
|
| Position: |
Senior Vice President and General Counsel |
Permanent person in charge of EU relations
| Surname, Name: |
Ms
Mindy Dooa
|
| Position: |
Communications Director |
Contact details:
| Contact details of organisation's head office: |
. Astellas Pharma Europe Ltd, Lovett House Lovett Road
Middlesex TW18 3AZ
UNITED KINGDOM
|
| Telephone number: |
(+44178) 4419 400 |
| Fax number: |
(+) |
| Other contact information: |
|
Goals / remit
| Goals / remit of the organisation: |
Astellas is one of the leading pharmaceutical companies in the world. As a young, forward thinking company with a rich heritage, Astellas is dedicated to improving peoples’ lives through the introduction of innovative and reliable pharmaceutical products. In everything we do we are guided by our ethos of CHANGING TOMORROW to create a brighter future for all our stakeholders – above all for patients.
Astellas Pharma Europe Ltd. (APEL) is headquartered in the UK and has 21 Sales Affiliates across Europe, the Middle East and Africa. In addition to its 21 Sales Affiliates, APEL has 14 Promotional Offices, three Manufacturing Plants and one Research & Development Centre in Europe. Employing over 4,000 people, APEL is committed to expanding its operations in these important regions.
With significant ongoing investment in R&D, Astellas continues to strengthen its capabilities as a research-driven pharmaceutical company, bringing effective therapies to patients and continuing to build trusted networks amongst physicians and partners.
In Europe, Astellas’ strategic focus and core expertise lie in the therapy areas of Transplantation, Urology, Dermatology, Anti-Infectives and Pain Management. In addition, Astellas is committed to growing a strong presence in the field of Oncology.
|
|
The organisation's fields of interests are:
|
|
Number of persons engaged in activities falling under the scope of the Transparency Register
| Number of persons: |
5
|
|
Complementary information:
|
|
Persons accredited for access to European Parliament premises
Activities
Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:
|
|
Fields of interest for e-mail alerts on consultations and roadmaps;
| Fields declared by the organisation: |
- Communication
- External Relations
- Public Health
- Research and Technology
|
Networking
Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.
|
Astellas Pharma Europe Ltd, is a member of EFPIA.
|
Financial data
| Financial year: |
03/2012
-
04/2012
|
|
Estimated costs to the organisation directly related to representing interests to EU institutions in that year:
|
250000
€ - 300000
€
|
|
Amount and source of funding received from the EU institutions in financial year n-1 of registration
|
|
Procurement:
|
0 €
|
|
Grants:
|
0 €
|
Other (financial) information provided by the organisation:
|
|
|
